Cyramza 500 MG/50 ML vial 50ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBP0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,609
Award facts
- Contract value 100% obligated
- $10,608.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $10,608.84 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cyramza 500 mg/50 mL vials. The delivery order, with an ultimate completion date of December 26, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for supporting Department of Defense pharmaceutical supply needs worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through numerous delivery orders and purchase orders from the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses an extensive range of pharmaceuticals including oncology treatments, biologics, vaccines, and specialty pharmaceuticals, positioning it to serve diverse and specialized medical requirements across military healthcare facilities globally. The underlying PPV-G GEN V IDC, designated as contract SPE2DR, was awarded on November 13, 2025, with a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods.
Quick answers
Who was awarded contract SPE2DR26FFBP0?
SPE2DR26FFBP0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FFBP0 worth?
The government has obligated $10,609 on SPE2DR26FFBP0.
Is contract SPE2DR26FFBP0 an order under another contract?
Yes. SPE2DR26FFBP0 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBP0 competed?
The extent of competition for SPE2DR26FFBP0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award